- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
Merck's product, Enflonsia, received approval from the FDA in the United States on August 28, 2025.
3 reports, 1 independent
Updated Aug 28
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Merck's product, Enflonsia, received approval from the FDA in the United States on August 28, 2025.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.Also in this story
- Merck is seeking FDA approval for its drug Winrevair, based on data from the ZENITH, HYPERION, and Stellar studies.
- The FDA is reviewing TAR-200 for approval, a process involving major pharmaceutical companies like Merck, AstraZeneca, and Pfizer in the oncology space.
- FDA granted Breakthrough Therapy designation for a drug developed by Merck.
- Ipsen received regulatory approval for Cabometyx, marking a competitive development with Merck in the renal cell carcinoma space.
Within A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
The entities involved
Coverage
Newest first; wire copies grouped- ZacksWill Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line? Merck’s MRK second-largest product Gardasil is a vaccine for the prevention of certain cancers caused by human papillomavirus (HPV).
- Unknown outlet
- Unknown outlet